La tunisie Medicale - 2022 ; Vol 100 ( n°011 ) : 775-781
[ 885 times seen ]
Introduction: Type1 primary hyperoxaluria is an infrequent autosomal recessive metabolic disease characterized by the accumulation of calcium oxalate in the kidney, which leads to end stage renal disease. In fact, the diagnosis of this disease is mandatory in order to avoid graft loss. Aim: To assess the incidence of primary hyperoxaluria and to develop the diagnostic value of bone marrow infiltration by calcium oxalate in uremic stone former patients. Methods: This study was conducted on a cohort of stone former patients identified in the south of Tunisia over a period of 18 years. Baseline characteristics were recorded. Clinical and laboratory data were collected on chart review. Secondary forms of hyperoxaluria were excluded. Bone marrow aspirate was performed in uremic patients from this cohort because early hyperoxaluria was suspected. Diagnostic accuracy of this test relating to sensitivity, specificity, positive predictive value and negative predictive value were also calculated. Results: A cohort of 31 patients comprising 17 male patients and 14 female patients were identified. During this time of diagnosis, the patient’s ages ranged from 9 to 57 years old and 22 of them (70%) unfortunately died. Bone marrow aspirate was safely done in 16 uremic patients. It was positive in 12 patients and negative in 4 patients. Sensitivity, specificity, positive predictive value and negative predictive value were respectively 85%, 100%, 100% and 50%. Conclusion: The bone marrow examination represents both an easy and a worldwide feasible solution for the diagnosis of oxalosis, which affords an early diagnosis.
Key - Words
  1. Scriver CR. The metabolic & molecular bases of inherited disease. Vol. 4. New York; Montreal: McGraw-Hill; 2001.
  2. Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant. 1 août 2005;20(8):1525‑9.
  3. Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci. 7 oct 2014;111(40):14406‑11.
  4. Bobrowski AE, Langman CB. The Primary Hyperoxalurias. Semin Nephrol. mars 2008;28(2):152‑62.
  5. Chiovaro JC, Gaggar A. Crystalline Bone Marrow in Systemic Oxalosis. J Gen Intern Med. juin 2014;29(6):961‑961.
  6. Nachite F, Dref M, Fakhri A, Rais H. Primary hyperoxaluria detected by bone marrow biopsy: case report. BMC Clin Pathol. déc 2017;17(1):20.
  7. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias.Kidney Int. 2 juin 2009;75(12):1264‑71.
  8. Leumann E, Hoppe B. The Primary Hyperoxalurias. J Am Soc Nephrol. 1 sept 2001;12(9):1986‑93.
  9. Cochat P, Koch Nogueira PC, Mahmoud MA, Jamieson NV, Scheinman JI, Rolland MO. Primary hyperoxaluria in infants: Medical, ethical, and economic issues. J Pediatr. déc 1999;135(6):746‑50.
  10. BEN HMIDA M, HACHICHA M, Kamoun K, Hamida N, Kaddour N, Bahloul Z, et al. Two cases of oxalosis as a cause of resistance to recombinant human erythropoietin. Dial Transplant. 1996;25(12):858‑60.
  11. Finocchiaro P, Enia G, Zoccali C. Erythropoietin in primary oxalosis. J Nephrol. 1991;4:249‑50.
  12. Lorenzo V, Hernandez D, Dominguez M, Rodriguez A, Torres A. Oxalosis as a cause of absolute resistance to rHuEpo in chronic haemodialysis patients. Nephrol Dial Transplant. 1 janv 1992;7(11):1163‑4.
  13. Lavoratti G, Seracini D, Pela I, Materassi M, Vichi G, Dilollo S, et al. Resistance to recombinant human erythropoietin therapy in a child with renal failure due to primary hyperoxaluria type 1. Nephrol Dial Transplant. 1994;1645‑8.
  14. Malempati S, Joshi S, Lai S, Braner DAV, Tegtmeyer K. Bone Marrow Aspiration and Biopsy. N Engl J Med. 8 oct 2009;361(15):e28.
  15. van Stralen KJ, Stel VS, Reitsma JB, Dekker FW, Zoccali C, Jager KJ. Diagnostic methods I: sensitivity, specificity, and other measures of accuracy. Kidney Int. 2 juin 2009;75(12):1257‑63.
  16. Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernández D, Salido E. Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience. Kidney Int. 2 sept 2006;70(6):1115‑9.
  17. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. International Registry for Primary Hyperoxaluria. Am J Nephrol. 2005;25(3):290‑6.
  18. Milliner DS. The Primary Hyperoxalurias: An Algorithm for Diagnosis. Am J Nephrol. 2005;25(2):154‑60.
  19. Blau N, Leonard J, Hoffmann GF, Clarke JTR, éditeurs. Physician’s Guide to the Treatment and Follow-Up of Metabolic Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006.
  20. Daudon M, Jungers P, Bazin D. Peculiar Morphology of Stones in Primary Hyperoxaluria. N Engl J Med. 3 juill 2008;359(1):100‑2.
  21. Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, et al. Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol [Internet]. 13 juin 2022 [cité 28 déc 2022]; Disponible sur: https://doi. org/10.1007/s00467-022-05613-2
  22. Cochat P. Primary hyperoxaluria type 1. Kidney Int. 1 juin 1999;55(6):2533‑47.
  23. Williams EL, Acquaviva C, Amoroso A, Chevalier F, CoulterMackie M, Monico CG, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat. 2009;30(6):910‑7.
  24. Cochat P, Basmaison O. Current approaches to the management of primary hyperoxaluria. Arch Dis Child. 2000;82(6):470‑3.
  25. Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: A conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci. 10 juin 2003;100(12):7277‑82.
  26. Kanoun H, Jarraya F, Maalej B, Lahiani A, Mahfoudh H, Makni F, et al. Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations. BMC Nephrol. déc 2017;18(1):303.
  27. Mbarek IB, Abroug S, Omezzine A, Zellama D, Achour A, Harbi A, et al. Selected AGXT gene mutations analysis provides a genetic diagnosis in 28% of Tunisian patients with primary hyperoxaluria. BMC Nephrol. 25 mai 2011;12(1):25.
  28. Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 1 mars 2010;77(5):443‑9.
  29. M’DIMEGH S, AQUAVIVA-BOURDAIN C, OMEZZINE A, M’BAREK I, SOUCHE G, ZELLAMA D, et al. A novel mutation in the AGXT gene causing primary hyperoxaluria type I: genotype–phenotype correlation. J Genet. 1 sept 2016;95(3):659‑66.
  30. Agrebi I, Kanoun H, Kammoun K, Yaich S, Turki M, Mseddi MA, et al. Primary hyperoxaluria type 1: report of the worldwide largest family. Int Urol Nephrol. 1 juill 2022;54(7):1773‑4.
  31. Rinat C, Wanders RJA, Drukker A, Halle D, Frishberg Y. Primary Hyperoxaluria Type I: A Model for Multiple Mutations in a Monogenic Disease within a Distinct Ethnic Group. J Am Soc Nephrol. 1 nov 1999;10(11):2352‑8.
  32. Kamoun A, Lakhoua R. End-stage renal disease of the Tunisian child: epidemiology, etiologies, and outcome. Pediatr Nephrol. 1 août 1996;10(4):479‑82.
  33. Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 1 oct 2003;18(10):986‑91.
  34. van Woerden CS, Groothoff JW, Wanders RJA, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant. 1 févr 2003;18(2):273‑9.
  35. Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N, et al. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant. 1 janv 1995;10(supp8):3‑7.
  36. Kopp N, Leumann E. Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant. 1 déc 1995;10(12):2224‑7.
  37. Kerkeni E, Monastiri K, Seket B, Guediche MN, Ben Cheikh H. Interplay of Socio-economic Factors, Consanguinity, Fertility, and Offspring Mortality in Monastir, Tunisia. Croat Med J. oct 2007;48(5):701‑7.
  38. Kamoun A, Daudon M, Zghal A, Lasram L, Ben Maiz H, Belkahia C, et al. Hyperoxalurie primitive: l’expérience tunisienne à propos de 24 cas pédiatriques. Néphrologie. 1997;18(2):59‑64.
  39. Belhaj R, Hayder N, Gargueh T, Zorguati M, Marrakchi O, Abdelhak S, et al. Diagnostic biochimique et moléculaire de l’hyperoxalurie primaire de type 1 : étude tunisienne à propos de 15 cas. Pathol Biol. août 2011;59(4):e97‑102.
  40. Chemli: Primary hyperoxaluria in children in central TunisiaGoogle Scholar.
  41. Fifth Workshop on Primary Hyperoxaluria 12/13 March 1999, Kappel/Zurich (Organized by Ernst Leumann, Zurich). Nephrol Dial Transplant. 1 nov 1999;14(11):2784‑2784.
  42. Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 1 mars 2010;77(5):443‑9.
  43. Stroke in Primary Hyperoxaluria Type I - Rao - 2014 - Journal of Neuroimaging - Wiley Online Library.
  44. Dieudonné Y, Eprinchard L, Léon E, Oswald P, Gressel A, Carre S, et al. Paraplegia as a presentation of primary hyperoxaluria. CEN Case Rep. 1 nov 2018;7(2):313‑5.
  45. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, et al. Cardiac Abnormalities in Primary Hyperoxaluria. Circ J. 2010;74(11):2403‑9.
  46. Arat N, Akyıldız M, Tellioğlu G, Tokat Y. Cardiac involvement of primary hyperoxaluria accompanied by non-compaction cardiomyopathy and patent ductus arteriosus. Kalp tutulumu olan primer hiperoksalürili bir olguda patent duktus arteriyozusun eşlik ettiği non kompaksiyon kardiyomiyopati [Internet]. 2015 [cité 20 août 2019]; Disponible sur: http://acikerisim.demiroglu.
  47. Xie X, Zhang X. Primary Hyperoxaluria. N Engl J Med. 10 mars 2022;386(10):976‑976.
  48. Beck BB, Hoppe B. Is there a genotype–phenotype correlation in primary hyperoxaluria type 1? Kidney Int. sept 2006;70(6):984‑6.
  49. Ben MH, Mhiri C, Mnif J, Hachicha J, Kchaou MS, Riffle G, et al. Primary brain lymphoma in a renal transplant patient: unsuccessful intrathecal treatment with anti-B cell monoclonal antibodies (anti-CD21). Transplant Proc. avr 1995;27(2):1779‑80.
  50. Madiwale C, Murlidharan P, Hase NK. Recurrence of primary hyperoxaluria: An avoidable catastrophe following kidney transplant. J Postgrad Med. 7 janv 2008;54(3):206.
  51. Kim HH, Koh HI, Ku BI, Lee HS. Late-onset primary hyperoxaluria diagnosed after renal transplantation presented with early recurrence of disease. Nephrol Dial Transplant. 1 août 2005;20(8):1738‑40.
  52. Malakoutian T, Yousefi F, Houshmand M, Mohammadi R, Aryani O, Pargoo EM, et al. Recurrence of primary hyperoxaluria after kidney transplantation. Iran J Kidney Dis. 2011;5(6):429‑33.
  53. Mnif K, Yaich S, Mars M, Kammoun K, Fendri F, Charfeddine K, et al. Crystalline Nephropathy in Renal Transplant: A Series of 4 Cases. Indian J Nephrol. 2018;28(6):472‑6.
  54. Woerden CS van, Groothoff JW, Wijburg FA, Waterham HR, Wanders RJA, Janssen MJW, et al. Primary Hyperoxaluria Remains Undiagnosed in Patients with Hyperoxaluria and Recurrent Urolithiasis. Clin Chem. 1 août 2007;53(8):1553‑5.
  55. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al. Transplantation Outcomes in Primary Hyperoxaluria: Transplantation in Primary Hyperoxaluria. Am J Transplant. nov 2010;10(11):2493‑501.
  56. Compagnon P, Metzler P, Samuel D, Camus C, Niaudet P, Durrbach A, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: The French Experience. Liver Transpl. 2014;20(12):1475‑85.
  57. Gupta A, Somers MJG, Baum MA. Treatment of primary hyperoxaluria type 1. Clin Kidney J. mai 2022;15(Suppl 1):i9‑13.
  58. Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, et al. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genet Med. 1 mars 2022;24(3):654‑62.
  59. Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, et al. Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Years of Practice. Clin J Am Soc Nephrol. 7 mars 2014;9(3):468‑77.
  60. Weerakkody RM. Primary hyperoxaluria type I importance of pre-transplant genetic screening. Saudi J Kidney Dis Transplant. 11 janv 2016;27(6):1283.
E-mail :
Password :
Remember Me Forgot password? Sign UP
Keywords most used
Tunisia treatment diagnosis Child surgery prognosis epidemiology Risk factors Children prevalence Crohn’s disease Breast cancer screening Cancer obesity
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !